Octreotide combined with goserelin in the therapy of advanced pancreatic cancer-results of a pilot study and review of the literature

Journal of Cancer Research and Clinical Oncology

Volumn 123, Issue 1, 1997, Pages 45-52

  Fazeny, B ^a   Baur, M ^b   Prohaska, M ^c   Hudec, M ^a   Kremnitzer, M ^c   Meryn, S ^d   Huber, H ^a   Grunt, T ^a   Tuchmann, A ^c   Dittrich, C ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d Evangelisches Krankenhaus Vienna   (Austria)

Author keywords

Goserelin; Octreotide; Pancreatic cancer

Indexed keywords

GOSERELIN; OCTREOTIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GOSERELIN; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OCTREOTIDE; PANCREATIC NEOPLASMS; PILOT PROJECTS;

EID: 0031060236     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01212614     Document Type: Article

References (39)

1. Allegretti A, Lionetto R, Saccomanno S, Paganuzzi M, Onetto M, Martinoli C, Rollandi G, Marugo M, Fazzuoli L, Pugliese V et il gruoppo Ligure per lo studio del pancreas (1993) LH-RH analogue treatment of adenocarcinoma of the pancreas: a phase II study. Oncology 50:77-80
2. Andren-Sandberg A (1989) Androgen influence on exocrine pancreatic cancer. Int J Pancreatol 4:363-369
3. Bauer W, Briner U, Doepfner W (1982) SMS 201 995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133-1140
4. Büchler M, Kübel R, Klapdor R (1989) Immunotherapy of pancreatic cancer with monoclonal antibody BW494: results from a multicentric phase I-II trial. In, Beger HG, Büchler M, Reisfeld RA, Schulz G (eds) Cancer therapy. Springer, Berlin Heidelberg New York, pp 32-47
5. Canobbio L, Boccardo F, Cannata D, Gallotti P, Epis R (1992) Treatment of advanced pancreatic cancer with the somatostatin analogue BIM 23014. Cancer 69:648-650
6. Cascinu S, Del Ferro E, Catalano G (1995) A randomised trial of octreotide vs best supportive care only in advanced cancer patients refractory to chemotherapy. Br J Cancer 71:97-101
7. Corbishley TP, Iqbal MJ, Johnson PJ, Williams R (1984) Progesterone receptors in malignant and foetal pancreatic tissue. IRCS Med Sci 12:575-576
8. Corbishley TP, Iqbal MJ, Wilkinson ML, Williams R (1986) Androgen receptor in human and malignant pancreatic tissue and cell lines. Cancer 57:1992-1995
9. Del Pora E, Neufeld K, Schlütter F (1986) Endocrine profile of a long-acting somatostatin derivate SMS 201-995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol 111:433-499
10. Fekete M, Zalatnai A, Comaru-Schally AM, Schally AV (1989a) Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 4:521-528
11. Fekete M, Zalatnai A, Schally AV (1989b) Presence of membrane binding sites for (D-TRP6)-luteinizing hormone-releasing hormone in experimental pancreatic cancer. Cancer Lett 45:87-91
12. Frieß H, Büchler M, Krüger M, Beger HG (1992) Treatment of duct carcinoma of the pancreas with the LH-RH analogue buserelin. Pancreas 7:516-521
13. Frieß H, Büchler M, Beglinger Ch, Weber A, Kunz J, Fritsch K, Beger HG (1993a) Low dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 8:540-545
14. Frieß H, Büchler M, Ebert M, Malfertheiner P, Dennler HJ, Beger HG (1993b) Treatment of advanced pancreatic cancer with high dose octreotide. Int J Pancreatol 14:290-291
15. Gonzalez-Barcena D, Ibarra-Olmos MA, Garcia-Carrasco F, Gutierrez-Samperso C, Comaru-Schally AM, Schally AV (1989) Influence of D-Trp-6-LH-RH on the survival time in patients with advanced pancreatic cancer. Biomed Pharmacother 43:313-317
16. Greenway B, Iqubal MJ, Johnson PJ & Williams R (1981) Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J 283:751-753
17. Hanna WT and Maull KI (1990) Sandostatin-induced thrombocytopenia. South Med J 83:77
18. Hierowski MT, Liebow C, Dusapin K, Schally AV (1985) Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIAPa CA2 cell lines. FEBS Lett 179:252-256
19. Huguier M, Samama G, Testart J, Mauban S, Fingerhut A, Nassar J, Houry S, Jaeck D, De Mestier P, Favre JP, Michot F, Vidrequin A, Mantion G, Veyrieres M, Fourtanier G, Lointier P, Gignoux M (1992) Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). Am J Surg 146:348-353
20. Klijn JGM, Setyono-Han B, Bakker GH, Henkelman MS, Portengen H, Foekens JA (1987) Effects of somatostatin analog (Sandostatin) treatment in experimental and human cancer. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal manipulation of cancer: peptides, growth factors and new (anti) steroidal agents. (EORTC monograph series, vol 18) Raven, New York, pp 459-468
21. Klijn JGM, Hoff AM, Planting ASTh, Verweij J, Kok T, Lamberts SWJ, Portengen H, Foekens JA (1990) Treatment of patients with metastatic pancreatic and gastrointestinal tumors with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 62:627-630
22. Lamberts SWJ, Van der Lely AJ, De Herder WW, Hofland LJ (1996) Octreotide. N Engl J Med 334:246-254
23. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
24. Redding TW, Schally AV (1984) Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci USA 81:248-252
25. Reubi JC, Horisberger U, Essed CE, Jeekel J, Klijn JGH, Lamberts SWJ (1988) Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 95:760-763
26. Rosenberg L, Barkun AN, Denis MH, Pollak M (1995) Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 75:23-28
27. Scambia G, Benedetti BP, Baiocchi G, Perrone L, Iacobelli S, Mancuso S (1988) Antiproliferative effects of somatostatin analog SMS 201 995 on three human breast cancer cell lines. J Cancer Res Clin Oncol 144:106-108
28. Schally AV (1988) Oncological applications of somatostatin analogues. Cancer Res 48:6977-6985
29. Serrano MJ, Liebow C, Reilly C, Shally AV (1988) LH-RH analogue causes direct inhibition of growth of pancreatic cancer cells in culture. Pancreas 3:617
30. Sperti C, Fasquali C, Catalini S, Alfano D'Andrea A, Militello C, Piccoli A, Pedrazzoli S (1992) Hormonal treatment of advanced pancreatic cancer with LH-RH analogue. European J Surg Oncol 18:267-271
31. Suri P, Lipton A, Harvey HA, Wyszynski E, Dixon R, Hamilton RW (1991) Hormonal treatment of pancreatic carcinoma with GNRH and somatostatin analogs. Proc Am Soc Clin Oncol 10:302
32. Szende B, Srkalovic G, Timar J, Mulchahey JJ, Neill JD, Lapis K, Csikos A, Szenpeshazi K, Schally A (1991) Localization of receptors for luteinizing hormone-releasing hormone in pancreatic and mammary cancer cells. Proc Natl Acad Sci USA 88:4153-4156
33. UICC International Union against Cancer (1987) TNM Klassifikation maligner Tumoren, vol 4. Springer, Berlin Heidelberg New York
34. Wagener DJTh, Mulder PHM de, Wils JA (1994) Multimodality treatment of locally advanced pancreatic cancer. Annal Oncol 5 [Suppl 3]: 81-86
35. Wagener DJTh, Verdonk HER, Dirix LY, Catimel G, Siegenthaler P, Buitenhuis M, Methieu-Boué, Verweij J (1995) Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 6:129-132
36. Wong A and Chan A (1993) Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. Cancer 71:2200-2203
37. World Health Organization (WHO) (1990) International classification of disease for oncology, 2nd edn WHO, Geneva
38. Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya A, Ihara Y, Li Q, Imura H, Seino S, Seino Y (1993) Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun 2:844-852
39. Zalatnai A, Schally AV (1989) Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules. Cancer Res 49: 1810-1815